Latest news

Kitov Reports KIT-302’s Beneficial Blood Pressure Effects from Phase III Trial

December 17, 2015 Tel Aviv, Israel – Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development,

December 17, 2015 12:13 pm Kitov Read More »

Kitov’s Phase III Trial Successfully Meets Primary Efficacy Endpoint

December 15, 2015 Tel Aviv, Israel – Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development,

December 15, 2015 12:14 pm Kitov Read More »

Kitov Completes Patient Recruitment for Phase III Clinical Trial for KIT-302

October 21, 2015, Tel Aviv, Israel – Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced

October 21, 2015 8:07 am Kitov Read More »

Kitov Announces FDA Approval of CMC Work Plan

July 1, 2015, Tel Aviv, Israel – Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced

July 1, 2015 8:08 am Kitov Read More »